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Background: Comorbid anxiety disorders are extremely prevalent in bipolar disorder (BD) and have substantial
impact on the course of illness. Limited evidence regarding treatment factors has led to a renewal of research
efforts examining both the impact of treatments on comorbid anxiety and the impact of comorbid anxiety on
treatments. The current study examines the impact of comorbid anxiety disorders on response to two psychosocial
interventions for BD.
Methods: A sample of 204 patients with BD took part in the study. Of them, 41.7% had a comorbid anxiety
disorder. All participants received either individual cognitive-behavioral therapy or group psychoeducation for BD.
Evaluations included complete pretreatment and 18-month follow-up assessments of mood and anxiety symptoms,
functioning, medication compliance, dysfunctional attitudes, and coping style. Outcome was compared based on
the presence or absence of a comorbid anxiety disorder.
Results and discussion: The participants with comorbid anxiety disorders ranked more severe than those without
on several measures. Despite more severe illness characteristics, the magnitude of their treatment gains was
equivalent or superior to that of the participants without anxiety disorders on a variety of outcome measures.
Although the treatments did not specifically target the anxiety disorder, the participants made significant
improvements in anxiety symptoms. Despite greater illness severity, patients with comorbid anxiety disorders can
make substantial gains from psychosocial interventions targeting BD. Even in the presence of an anxiety disorder,
they are able to attend to the content of the psychosocial treatments and apply it to better manage their
condition. The presence of a comorbid anxiety disorder should not be considered a deterrent to offering BD-
focused psychosocial treatments.
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Bipolar disorder (BD) is a complex, chronic mood disorder
involving repeated episodes of depression and mania/hypo-
mania (American Psychiatric Association 2001). In
addition to multiple relapses of mood episodes (Schaffer
et al. 2006), individuals living with BD also experience* Correspondence: lisa.hawke@outlook.com
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in any medium, provided the original work is psubstantial symptoms between episodes (Benazzi 2004;
Paykel et al. 2006).
Complicating the course of illness, psychiatric comorbid-
ity is very highly prevalent (Schaffer et al. 2006). Anx-
iety disorders are among the most highly prevalent
comorbidities associated with BD. Epidemiological studies
show that as many as 74.9% of individuals with BD have at
least one anxiety disorder at some point in their lives
(Merikangas et al. 2007). Unfortunately, comorbid anxiety
disorders are associated with more affective relapses, in-
creased suicidality, sleep disturbances, decreased work andn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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ment (Hawke et al. 2013; Freeman et al. 2002). Further-
more, they appear to reduce the effectiveness of mood
stabilizers (Keller 2006) and increase nonadherence to
pharmacotherapy (Perlis et al. 2010), substantially compli-
cating the pharmacological treatment approach (Schaffer
et al. 2012).
A recent review of publication trends revealed that al-
though the characteristics of the bipolar-anxiety comorbid-
ity set have been described in detail in the literature, there
is a paucity of research examining its treatment factors
(Provencher et al. 2012). Several studies have suggested that
comorbid anxiety disorders interfere with treatment re-
sponse (El-Mallakh and Hollifield 2008). However, treat-
ment research has largely consisted of small case studies
and preliminary reports, with few large-scale trials. Further-
more, most research has addressed pharmacotherapy,
surprisingly few examining psychosocial interventions
(Provencher et al. 2012; Provencher et al. 2011a,b).
Nevertheless, the potential benefits of psychosocial inter-
ventions for comorbid anxiety have been discussed, and
three main approaches described. The first is an integrated
treatment approach, where anxiety-focused techniques are
built into a BD-focused treatment, producing moderate re-
sults (Williams et al. 2008; Dusser et al. 2009). A second
approach is sequential, i.e., targeting the BD and anxiety
disorder with two specific, separate interventions; pilot
tests of this approach have also produced moderate results
(e.g., Mueser et al. 2004). A third approach is a comprom-
ise between the two, i.e., the modular treatment of
comorbidities within a standard CBT protocol (Otto and
Reilly-Harrington 2002; Thienot et al. 2013). However, no
studies have been identified that test this approach.
The limited evidence regarding the impact of comor-
bid anxiety disorders on psychosocial treatments and,
conversely, the impact of psychosocial treatments on co-
morbid anxiety disorders led Provencher et al. (2012;
2011a, b) to call for a renewal of research efforts exam-
ining the reciprocal relationship between comorbid anx-
iety and BD treatments.
Further to those recommendations, this study is a sec-
ondary analysis of data from a randomized controlled
trial comparing cognitive-behavioral therapy (CBT) with
psychoeducation for BD (Parikh et al. 2012). The pri-
mary findings of that study were that the two interven-
tions have equivalent impacts on affective symptoms
and relapses. This study reanalyzes the data to determine




A total of 204 participants took part in the study. The
average age was 40.9 years (SD = 10.7). The participantshad type I BD (BD-I, 72.1%) or type II BD (BD-II,
27.9%), confirmed with the Structured Clinical Interview
for DSM-IV Axis I Disorders (SCID-I) (First et al. 2002).
The inclusion criteria included having at least two epi-
sodes of significant symptoms or full episodes within the
previous 3 years but no episode in the month preceding
randomization. The exclusion criteria included current
substance dependence, severe borderline personality dis-
order, antisocial personality disorder, life-threatening
medical illness, acute suicidality or homicidality, or sig-
nificant cognitive deficits or language problems.
Procedure
A detailed description of the study is provided elsewhere
(Parikh et al. 2012). The participants were randomized,
without regard to illness severity, to individual CBT or
group psychoeducation for BD and treated on an out-
patient basis. Psychoeducation consisted of six didactic
90-min sessions drawn from a published manual (Bauer
and McBride 2003). The topics included illness recogni-
tion, treatment approaches, coping strategies, and the
creation of personal action plans for depression and
mania. CBT consisted of 20 individual 50-min sessions
from a published manual (Lam et al. 1999). The content
included psychoeducation on BD, a relapse action plan,
and additional cognitive-behavioral strategies such as be-
havioral self-monitoring and cognitive restructuring.
Evaluations were conducted by trained, experienced re-
search assistants. The number of sessions attended did
not differ based on the presence or absence of a comor-
bid anxiety disorder (t(202) = −0.761, p = 0.45). The
follow-up period was 18 months, and 160 participants
provided follow-up data. The study was approved by the
research ethics board of each participating medical cen-
ter, i.e., the University Health Network Research Ethics
Board, the Centre for Addiction and Mental Health Re-
search Ethics Board, the Douglas Mental Health Univer-
sity Institute Research Ethics Board, the St. Joseph's
Health Care Research Ethics Board, and the UBC Hos-
pital Research Ethics Board. Written informed consent
was obtained from all participants.
Measures
The diagnoses were established using the SCID-I (First
et al. 2002). The symptoms were assessed using the Longi-
tudinal Interval Follow-up Evaluation scale scores for
mania/hypomania, depression, and panic disorder (LIFE)
(Keller et al. 1987), the Clinician-Administered Rating Scale
for Mania (CARSM) (Altman et al. 1994), and the 21-item
Hamilton Rating Scale for Depression (HAMD) (Hamilton
1967). A specific anxiety scale was not employed in the
study; however, since the HAMD contains four items meas-
uring anxiety (psychic anxiety, somatic anxiety, hypochon-
driasis, and obsessive-compulsive symptoms), these items
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Anxiety scale. The 17-item HAMD total was calculated
with and without the anxiety items, for a classic HAMD-17
score and a reduced HAMD-Depression measure that ex-
plicitly excludes the anxiety component. Additional mea-
sures included the Global Assessment of Functioning (GAF)
(American Psychiatric Association 2001), the Social Adjust-
ment Scale (SAS) (Bauer et al. 2001; Glazer et al. 1980), the
Dysfunctional Attitudes Scale (DAS) (Weissman and Beck
1980), the Coping Inventory for the Prodromes of Mania
(CIPM) (Wong and Lam 1999), and a single-item rating
scale measuring medication compliance.
Analyses
Pretreatment and posttreatment analyses were con-
ducted to compare the participants with and without co-
morbid anxiety disorders. For weekly LIFE symptom
scores, a mean score was calculated for the first 4 weeks
and the last 4 weeks of the study to provide robust
symptom measurements. The mixed linear model was
employed, with an unstructured covariance matrix, to
manage dropouts and missing data. The analyses were
conducted using SPSS-21, with a significance criterion
of 0.05.
Results
The comorbid anxiety disorders were identified in 85
participants (41.7%). These included social phobia
(36.5% of the anxiety disorder subsample), panic dis-
order with or without agoraphobia (31.8%), agoraphobia
without panic disorder (4.7%), specific phobia (11.8%),
obsessive-compulsive disorder (11.8%), posttraumatic
stress disorder (10.6%), generalized anxiety disorderTable 1 Treatment impact on mood and anxiety symptoms b
No anxiety disorder Comorbid anxiety
disorder
Baseline 18 months Baseline 18 months
M (SD) M (SD) M (SD) M (SD)
Depression
LIFE-Depression 2.28 (1.43) 1.94 (1.23) 2.84 (1.55) 1.94 (1.35)
HAMD-17 5.82 (4.38) 4.18 (4.88) 8.39 (5.27) 5.02 (6.05)
HAMD-Depression 4.97 (3.69) 3.30 (3.80) 6.54 (4.29) 3.83 (5.04)
Mania
LIFE-Mania 1.39 (0.87) 1.17 (0.49) 1.41 (1.01) 1.15 (0.46)
CARSM 1.80 (2.61) 1.32 (3.16) 2.35 (3.71) 1.19 (3.19)
Anxiety
LIFE-Panic 1.01 (0.08) 1.02 (0.12) 1.25 (0.55) 1.09 (0.40)
HAMD-Anxiety 1.02 (1.40) 0.93 (1.45) 2.14 (1.80) 1.26 (1.70)
Significant effects are italicized. CARSM Clinician-Administered Rating Scale for Man
Anxiety, Hamilton Rating Scale for Depression, four anxiety items only, HAMD-Depre
Longitudinal Interval Follow-up Examination.(10.6%), and anxiety disorder not otherwise specified
(2.4%)a. There was no significant difference in age
(t(202) = 0.018, p = 0.99), sex (χ2(1) = 2.814, p = 0.09),
marital status (χ2(2) = 2.975, p = 0.23), and primary
diagnosis (BD-I vs. BD-II; χ2(1) = 1.058, p = 0.30) based
on the presence of a comorbid anxiety disorder.
The treatment impact on mood and anxiety symptoms
based on the presence of a comorbid anxiety disorder is
presented in Table 1. Significant time effects show that
over 18 months, the participants improved significantly
in depressive, manic/hypomanic, and anxiety symptoms,
with a nonsignificant trend toward improvement on the
LIFE-Panic scale. Significant anxiety disorder effects
show that the participants with comorbid anxiety disor-
ders ranked significantly more severely on HAMD-
Depression and both measures of anxiety symptoms.
Significant anxiety disorder × time interactions are ap-
parent on LIFE-Depression and both measures of anx-
iety, demonstrating that participants with anxiety
disorders make greater gains in anxiety and depressive
symptoms than those without. However, the absence of
interaction for manic/hypomanic symptoms shows
equivalent gains irrespective of the presence of a comor-
bid anxiety disorder.
The treatment impact on secondary outcome mea-
sures is presented in Table 2. Significant time effects
show improvements on measures of global functioning,
social functioning, medication compliance, dysfunctional
attitudes, and coping style. The significant main effects
for the presence of an anxiety disorder confirm that the
anxiety disorder group fares worse in a number of areas.
However, the absence of an anxiety disorder × time
interaction on any secondary outcome measure showsased on anxiety disorder comorbidity
Time effect Anxiety disorder
effect
Time × anxiety disorder
interaction
F p F p F p
20.16 <0.001 2.66 0.11 4.36 0.04
19.96 <0.001 7.49 0.01 2.35 0.13
22.54 <0.001 4.34 0.04 1.21 0.27
8.31 0.004 0.01 0.94 0.06 0.81
5.18 0.024 0.32 0.58 0.91 0.34
3.35 0.07 16.40 <0.001 4.08 0.047
8.01 0.005 14.75 <0.001 5.41 0.021
ia, HAMD-17 Hamilton Rating Scale for Depression, 17-item version, HAMD-
ssion Hamilton Rating Scale for Depression, excluding anxiety items, LIFE
Table 2 Treatment impact on secondary outcome variables based on anxiety disorder comorbidity




Baseline 18 months Baseline 18 months
M (SD) M (SD) M (SD) M (SD) F p F p F p
GAF 67.03 (10.76) 72.07 (14.26) 61.73 (10.50) 69.32 (13.43) 25.54 <0.001 7.42 0.007 0.53 0.47
SAS-Social 2.36 (1.16) 2.15 (0.83) 2.94 (1.41) 2.49 (1.25) 8.05 0.005 10.95 0.001 1.07 0.30
SAS-Overall 2.50 (0.88) 2.36 (0.82) 2.82 (0.81) 2.58 (0.73) 5.96 0.016 6.71 0.01 0.39 0.54
Compliance 1.46 (0.57) 1.66 (0.77) 1.36 (0.53) 1.51 (0.87) 6.74 0.011 1.74 0.19 0.11 0.74
DAS 130.17 (35.22) 113.57 (33.81) 140.27 (38.41) 124.57 (34.72) 31.09 <0.001 4.76 0.03 0.003 0.96
CIPM
Stimulation reduction 1.92 (0.57) 2.18 (0.63) 1.95 (0.55) 2.25 (0.57) 20.99 <0.001 0.47 0.49 0.25 0.62
Seek professional help 2.17 (0.86) 2.28 (0.73) 2.15 (0.82) 2.20 (0.82) 0.39 0.53 0.36 0.55 0.06 0.81
Problem-directed coping 2.17 (0.60) 2.47 (0.64) 2.11 (0.59) 2.44 (0.52) 29.25 <0.001 0.18 0.67 0.21 0.65
Denial/blame 2.21 (0.51) 1.98 (0.50) 2.12 (0.54) 1.91 (0.46) 15.20 0.001 1.90 0.17 0.02 0.90
Significant effects are italicized. CIPM Coping Inventory for the Prodromes of Mania, DAS Dysfunctional Attitude Scale, GAF Global Assessment of Functioning, SAS-
Overall Social Adjustment Scale-Global Overall Functioning, SAS-Social Social Adjustment Scale-Global Social Functioning.
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respective of the presence of a comorbid anxiety
disorder.
For comparison of the treatment conditions, the ana-
lyses were repeated with psychoeducation vs. CBT
treatment condition included as a covariate. None of
the three-way time × anxiety disorder × treatment
interaction effects approached statistical significance,
suggesting that the impact of the two treatments was
consistent in the presence a comorbid anxiety disorder.
Additional analyses were conducted to determine whether
the effects were accounted for by differential pharmaco-
logical treatment. Full pharmacological data was available
for a subsample of 114 participants. Chi-square tests show
that at baseline, the participants with comorbid anxiety dis-
orders were not more likely than those without anxiety
disorders to be taking either benzodiazepines (χ2 = 1.698,
p = 0.19) or antidepressants frequently used to treat anxiety
(χ2 = 1.013, p = 0.31). The same held true at the 18-month
follow-up assessment (benzodiazepines χ2 = 1.213, p = 0.27;
antidepressants χ2 = 0.164, p = 0.69).
Discussion
This study examined the differential impact of psychosocial
interventions for BD based on whether patients had a co-
morbid anxiety disorder. The results showed that although
those with anxiety disorders ranked more severe in several
areas, the amount of improvement they gained from the
treatments was equivalent or superior to the participants
without anxiety disorders. They made similar gains in both
CBT and psychoeducation. These results applied not only to
mood symptoms and functioning but also to anxiety and a
variety of secondary measures.
Among the notable findings, the participants with co-
morbid anxiety disorders had substantially higher anxietylevels when beginning treatment but made significant
gains on anxiety that partially bridged this gap. They also
made greater gains than the participants without comor-
bid anxiety on one measure of depression. This suggests
that even when not specifically targeting anxiety, BD-
specific interventions can have positive impacts on both
mood and anxiety. It may be that the treatments served as
a transdiagnostic exposure exercise that reduced anxiety
or taught participants to better identify their symptoms.
Alternatively, the treatments may have fostered improved
acceptance of the disorder, reducing their anxiety about
living with BD and being evaluated for it. Indeed,
psychoeducation has been shown to increase acceptance
of BD (Provencher et al. 2011a), while acceptance is asso-
ciated with lower depression and possibly anxiety (Bussing
et al. 2008). Equivalent treatment gains on dysfunctional
attitudes, coping styles, and medication compliance are
also encouraging since they show that comorbid anxiety
does not interfere with the ability to attend to the treat-
ment content and apply it to better manage their
condition.
Given the extremely high prevalence of comorbid
anxiety disorders (Merikangas et al. 2007; Hawke et al.
2013) and their negative impact on the course of ill-
ness (Hawke et al. 2013; Otto et al. 2006; Feske et al.
2000; Coryell et al. 2009), it is essential to consider co-
morbid anxiety in treatment research. However, there
is a paucity of research examining the impact of anx-
iety on response to common psychological interven-
tions for BD. This study adds to a small but growing
literature on the impact of comorbid anxiety disorders
on two forms of BD interventions. It also directly re-
sponds to a call for increased attention to this comor-
bidity set in treatment studies (Provencher et al. 2012;
Provencher et al. 2011a,b).
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of the bipolar-anxiety comorbidity set have been pro-
posed: (1) integrated, where anxiety-focused techniques
are built into a BD-focused treatment; (2) sequential,
where the BD and the anxiety disorder are targeted sep-
arately with disorder-specific interventions; and (3)
modular, where anxiety modules are inserted into a
standard BD treatment. Given that the impacts of the
psychosocial interventions in the current study were
equivalent irrespective of anxiety disorder status, this
study provides partial support for the relevance of the
sequential approach when interpreted in conjunction
with promising trials of psychotherapy for comorbid
anxiety (e.g., Mueser et al. 2004; Thienot et al. 2013).
Several studies have suggested that CBT-type interven-
tions might be particularly promising for comorbid anx-
iety disorders (Provencher et al. 2011a,b). For bipolar
disorder, a randomized controlled trial of CBT for BD
found that CBT was ineffective for patients with a more
severe, chronic course of illness (Scott et al. 2006). Al-
though that study did not specifically consider anxiety
disorders as a severity factor, many studies have demon-
strated that the course of illness is more severe in the
presence of a comorbid anxiety disorder (e.g., Hawke
et al. 2013; Freeman et al. 2002). Based on those find-
ings, the efficacy of CBT might be expected to be min-
imal in the presence of a comorbid anxiety disorder.
However, this is not the case in the current study. Al-
though the treatment gains did not completely bridge
the gap between the two groups on all measures, the
magnitude of the gains was significant and substantial.
Given equivalent or superior treatment gains, combined
with significant improvements in anxiety symptoms,
CBT and psychoeducation might be effectively combined
sequentially with anxiety-focused CBT-type interven-
tions to produce robust dual impacts. Alternatively,
more specific anxiety modules might be integrated into
these treatments to enhance impacts on anxiety.
Unfortunately, the combined and relative impact of
each sequential treatment component cannot be evalu-
ated within the framework of this study. Integrative re-
search is required to examine the efficacy and optimal
order of sequentially administered BD-specific and
anxiety-specific interventions. Also remaining to be ex-
amined is the additional benefit gained by adding anxiety
modules to existing treatments, as well as the differential
impact of sequential, integrated and modular treatment
approaches. Additional avenues for exploration include
the mechanism by which these interventions produce re-
ductions in anxiety symptoms and the differential impact
on the various anxiety disorders.
Study limitations include the absence of a comparative
treatment specifically targeting the comorbid anxiety
disorder and a lack of anxiety-specific and anxietydisorder-specific measures to assess the impact on the
anxiety disorder. Similarly, the sample sizes were insuffi-
cient to examine the specific impacts on the different
anxiety disorders. However, the increasingly common
use of transdiagnostic conceptualizations of and treat-
ments for anxiety disorders justifies the analyses of all
anxiety disorders combined (Norton and Philipp 2008).
An additional limitation is that the recruitment took
place primarily in academic medical centers; therefore,
the results may not be fully generalizable to patients in
the community.
Conclusion
In conclusion, this study shows that individuals with co-
morbid anxiety disorders can make substantial gains
from CBT and psychoeducation targeting BD, including
reductions in anxiety symptoms. Furthermore, the gains
they make in functioning, compliance, attitudes, and
coping styles are equivalent to those of patients without
comorbid anxiety disorders. The presence of a comorbid
anxiety disorder should not be considered a deterrent to
offering a patient BD-focused CBT or psychoeducation.
Endnote
aThe percentages do not sum to 100% due to anxiety
comorbidities.
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